论文部分内容阅读
目的 :检测非小细胞肺癌 MUC- 1的表达情况及其与临床分期和转移的相关性。方法 :应用反转录聚合酶链反应 (RT- PCR)和免疫组织化学方法在原发癌灶和转移淋巴结中检测 MU C- 1基因的表达水平。结果 :在5 6例非小细胞肺癌病例中 MU C- 1m RNA阳性表达率为 48.2 % ,MU C- 1蛋白阳性表达率为 5 3.6 %。临床分期中 期和 期患者阳性表达率 :MU C- 1m RNA为 33.3% ,MU C- 1蛋白为 40 % ,而 期患者则分别高达 6 5 .4%和6 9.2 % ,二者差异有显著性 (P<0 .0 5 )。原发癌灶和转移淋巴结的癌细胞 MUC- 1的染色强度可以从“+”增强到“+ +”,转移的癌细胞 MUC- 1高表达。结论 :MU C- 1是一种能较好反映非小细胞肺癌恶性程度和转移性的肿瘤标志物
Objective: To detect the expression of MUC-1 in non-small cell lung cancer and its correlation with clinical stage and metastasis. METHODS: The expression of MU C-1 gene was detected in primary and metastatic lymph nodes using reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. RESULTS: The positive rate of MU C-1 m RNA was 48.2% and the positive rate of MU C-1 protein was 5 3.6 % in 56 cases of non-small cell lung cancer. The positive expression rate of patients in the mid-phase and in the clinical stage: MU C-1m RNA was 33.3%, MU C-1 protein was 40%, and patients in the period were as high as 65.4% and 69.2% respectively. There was a significant difference between the two groups. (P<0.05). The staining intensity of the primary cancer cells and the metastatic lymph nodes MUC-1 can be increased from “+” to “+ +”, and the metastatic cancer cells MUC-1 is highly expressed. Conclusion: MU C-1 is a tumor marker that can better reflect the malignancy and metastasis of non-small cell lung cancer